Close Menu

technology development

The companies have expanded an existing partnership to allow physicians to order mental health PGx tests from the EHR and receive CME credit for learning about PGx.

The university also is developing a process for measuring phenotype risk scores as it continually adapts to changing technology and research needs.

Seattle-based Adaptive will develop in vitro diagnostic test kits for distribution, which will run on Illumina's NextSeq 550 Dx system.

The Chan Zuckerberg Initiative is leading efforts to build cloud infrastructure, scale the platform, and distribute data from the project.

Startup BioLizard will develop the algorithm to help Novigenix migrate its immuno-transcriptiomic assay for early colorectal cancer detection to a new NGS-based platform.

The Genomics Research and Innovation Network (GRIN) is a federated platform from three major pediatric hospitals to assist in research and treatment of rare diseases.

The partners are preparing to release two updates to Navify Tumor Board that support automatic importation of structured Foundation Medicine test reports.

Researchers focused on using existing computational methods to fill in gaps in the human microbiome without reference genomes.

The Wellcome Trust has granted the University of Dundee five more years of support to help bioinformaticians develop a web-compatible JavaScript version of the software.

Bioinformaticians at the Free University of Brussels have built a database, machine learning technology, and web platform for identifying elusive pathogenic gene pairs.

Pages

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.